200 related articles for article (PubMed ID: 23171275)
1. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
Paschal RD; Meeks SL; Neff AT
Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
[No Abstract] [Full Text] [Related]
2. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
[No Abstract] [Full Text] [Related]
3. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
5. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
6. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
[TBL] [Abstract][Full Text] [Related]
7. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
8. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
9. Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization.
Kruse-Jarres R
Haemophilia; 2014 Sep; 20 Suppl 6():1. PubMed ID: 24975699
[No Abstract] [Full Text] [Related]
10. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
11. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
[No Abstract] [Full Text] [Related]
12. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
Leissinger CA
Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
[TBL] [Abstract][Full Text] [Related]
13. Anti-factor-VIII inhibitors in haemophilia.
Lancet; 1989 Aug; 2(8659):363-4. PubMed ID: 2569554
[No Abstract] [Full Text] [Related]
14. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision.
Leblebisatan G; Sasmaz I; Antmen B; Kilinc Y; Sizmaz S; Yagmur M
Haemophilia; 2006 Mar; 12(2):187-9. PubMed ID: 16476096
[No Abstract] [Full Text] [Related]
15. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
[No Abstract] [Full Text] [Related]
17. Re-emergence of a low-titre factor VIII inhibitor after liver transplant.
Horton S; Martlew V; Wilde J; Thachil J
Haemophilia; 2012 May; 18(3):e69-71. PubMed ID: 22531024
[No Abstract] [Full Text] [Related]
18. Rituximab for the treatment of high titre inhibitors in mild haemophilia A.
Dolničar MB; Rajić V; Kitanovski L; Debeljak M
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s345-7. PubMed ID: 23522890
[No Abstract] [Full Text] [Related]
19. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
[No Abstract] [Full Text] [Related]
20. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
